TNG:EPA
Transgene SA
€ 0,68
arrow_downward
-0,73%(-0,0050) 1D
19 okt, 17:35:04 GMT+2 · EUR
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor TNG genereren…
Openen
€ 0,69
Hoog
€ 0,70
Laag
€ 0,68
Beursw.
189,70Â mln.
Gem. vol.
111,65K
Volume
53,57K
52 wk hoog
€ 1,50
52 wk laag
€ 0,68
WPA
€ -0,17
Uitstaande aandelen
278,56Â mln.
Aantal medewerkers
152
Openen
€ 0,69
Hoog
€ 0,70
Laag
€ 0,68
Beursw.
189,70Â mln.
Gem. vol.
111,65K
Volume
53,57K
52 wk hoog
€ 1,50
52 wk laag
€ 0,68
WPA
€ -0,17
Uitstaande aandelen
278,56Â mln.
Aantal medewerkers
152
Nieuwsartikelen
Van webbronnen en nieuwspartners
Vietnam.vn
·
2 dagen geleden
De S&P 500 kende de scherpste wekelijkse daling sinds juni 2026.
MarketScreener Nederland
·
4 uur geleden
S&P 500 en Nasdaq stijgen nu AI-aandelen zich herstellen in aanloop naar cijfers
Simply Wall Street
·
1 uur geleden
Why Is Recursion Pharmaceuticals (RXRX) Drawing Attention After AI Drug And Trial Milestones?
qz.com
·
1 uur geleden
Eric Criscuolo on the Dow Jones climbing the wall of worry
Profiel
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Over Transgene SA